Alnylam Pharmaceuticals | Passifs Courants



Current Liabilities Changement Date
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Arrowhead Research USD 93.76M 9.41M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Incyte USD 1.64B 140.2M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
Moderna USD 2.21B 5M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Sanofi 30.03B 5.82B 2024-06
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Takeda JPY 2.1T 289.27B 2024-12
Tectonic Therapeutic USD 17.32M 8.68M 2024-09
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12
Xencor USD 87.43M 4.54M 2024-12



Alnylam Pharmaceuticals Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.